ZYMERON CORPORATION — Department of Defense SBIR Phase II: DHA201-002
ZYMERON CORPORATION — SBIR Phase II award from Department of Defense.
Phase II SBIR prototype / development signal
- Phase II is where Department of Defense funds deeper R&D after feasibility. Incumbents with Phase II history are serious competitors on adjacent topics.
- Use this award as past-performance context and to map customer organizations for STRATFI/TACFI-style transition planning.
- At $2,999,993, this is a large obligation for typical SBIR Phase sizing — worth reviewing for scope breadth and teaming opportunity.
- Topic code DHA201-002 links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $2,999,993
- Agency
- Department of Defense · Defense Health Program
- Program / Phase
- SBIR · Phase II
- Topic
- DHA201-002
- Solicitation
- 00.1
- NAICS
- —
- Place of performance
- NC
- Period
- 2022-02-07 → 2024-06-06
Description
Acute radiation syndrome (ARS) is a severe illness that occurs when a person is exposed to high levels of ionizing radiation, typically within a relatively short period. The hematopoietic system is most vulnerable for radiation exposure since mild symptoms may occur at the exposure dose of as low as 0.3 Gy, and severe ionizing radiation-induced hematopoietic failure usually results in lethal infections. So far, the United States Food and Drug Administration (US FDA) has approved four post-exposure therapeutics to treat the hematopoietic ARS. Pre-exposure prophylactic (PrEP) radiation medical countermeasures (MCMs) are designed to be administered prior to radiation exposure to prevent harmful impacts of radiation exposure, increase survival, and reduce the recovery time and cost. US military personnel may be exposed to ionizing radiation during military operations in known radiologically contaminated areas, and thus effective, safe PrEP MCMs against hematopoietic ARS are clearly urgent medical demands. Therefore, Zymeron is developing RadioDefender, a safe and easy-to-use PrEP radiation MCM based on amifostine that provides significant radioprotection on the hematopoietic system.